Chapter 53: Drugs for Benign Prostatic Hyperplasia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a patient walks into your clinic, he's 65, and his prostate has ballooned to a massive 80 grams.

I mean that is like four times its normal size.

Right, that's huge.

Yeah, but here's the thing, he feels absolutely fine, no urgency, no straining at all, but then right in the next room you have another patient whose prostate is barely enlarged, maybe like 25 grams, and he is in absolute agony.

Oh yeah, the dysphoria, the constant urge.

Exactly, just a maddening sensation of incomplete emptying.

So why does that happen?

How can the physical size of the gland completely fail to correlate with how severe the symptoms are?

Well, it's a paradox that trips up a lot of clinicians honestly, and it's exactly why prescribing for benign prostatic hyperplasia or BPH requires a really deep understanding of what is actually happening at the cellular level.

Because you aren't just treating a big gland, right?

Exactly, you're treating specific types of cellular overgrowth that require entirely different pharmacological tools.

Which is exactly what we are mastering today.

So if you are joining us, you're likely an advanced practice nursing or physician assistant student gearing up for clinicals, or maybe you're staring down a pretty complex pharmacotherapeutics exam.

We've all been there.

Oh absolutely.

So consider this your custom tailored deep dive into the pharmacology of BPH.

Today we are diving into chapter 53 of Len's pharmacotherapeutics.

We're going to strip away the rote memorization and focus purely on the clinical logic.

Because you know by the end of this, you won't just know which drug to prescribe.

You will understand the exact mechanism, the pharmacokinetics, and the well, the prescribing traps that can really severely impact your patients.

Right, because the therapeutic goals have to dictate your rational drug selection.

We have to map the mechanism of the obstruction to the right drug class.

And then use that selection to guide safe dosing and monitoring.

It's all connected.

Okay, let's unpack this.

We have to start with that paradox I mentioned earlier.

How does a massive prostate cause zero symptoms while a slightly enlarged one just causes absolute misery?

So it comes down to the two distinct types of tissue that are driving the hyperplasia.

You have an overgrowth of epithelial or glandular cells, and then you have an overgrowth of smooth muscle cells.

Okay, so epithelial and smooth muscle.

Right.

When the epithelial cells overgrow, they basically take up physical space, they press inward on the urethra, and that causes mechanical obstruction.

Makes sense.

But when the smooth muscle cells overgrow, they increase the dynamic tension in the prostate capsule and the bladder neck.

Yeah.

And that causes a dynamic obstruction.

Ah, okay.

So mechanical versus dynamic.

Let's try to visualize this for a second.

If treating a patient's BPH is like trying to drive a heavy truck up a hill, the epithelial overgrowth, that mechanical obstruction, is like having a massive load of cargo in the trunk.

I like that.

It's physical bulk just weighing the whole system down.

Yeah, exactly.

And the smooth muscle overgrowth, the dynamic obstruction, that is like trying to drive with the emergency brake tightly pulled.

That is a perfect analogy.

Yeah.

It perfectly illustrates why the treatment modalities are so different.

I mean, if the patient has a lot of cargo, like a bulky 80 -gram prostate, but their emergency brake isn't engaged, they might not have severe symptoms.

Right.

The flow can still happen just with maybe a bit more physical resistance.

Exactly.

But if a patient has a smaller prostate, so very little cargo, yet that emergency brake of smooth muscle is yanked all the way up, they're going to experience intense immediate urinary symptoms.

Which logically brings us to how we actually manage this.

I mean, for minimal symptoms, the text says we do watchful weighting.

Right.

Just monitor.

And for severe complications like obstructive nephropathy or recurrent UTIs, we send them straight to urology for a surgical resection.

The invasive route.

But right in the middle, the symptomatic patient sitting right there in your exam room, we use drug therapy.

So let's tackle that heavy cargo first.

Yeah.

How do we shrink that epithelial mechanical obstruction?

Well, we use the five alpha reductase inhibitors, or five ARIs.

And the two primary agents here are finasteride and dudasteride.

Okay.

Finasteride and dudasteride.

Yeah.

And the mechanism is actually pretty fascinating because it's highly targeted.

These drugs inhibit five alpha reductase, which is the enzyme responsible for converting circulating testosterone into dihydrotestosterone, or DHT.

And DHT is the active androgen in the prostate.

Right.

Exactly.

DHT is what drives the proliferation of those epithelial cells.

Okay.

So by blocking that conversion, we basically starve the epithelial tissue of its primary growth factor.

That's it.

Exactly.

Finasteride actually reduces serum DHT levels by about 70%.

And without DHT, the epithelial cells undergo apoptosis.

Wow.

They just die off.

Yeah.

The tissue literally regresses and shrinks, which decreases that mechanical pressure on the urethra.

But wait, if we are interfering with the conversion of testosterone to DHT, aren't we like plummeting their overall testosterone levels?

I mean, that sounds like a recipe for a systemic disaster.

Yeah.

It's a super common misconception.

But no, the serum testosterone levels actually remain completely intact.

Yeah.

And in some cases, they slightly elevate because less of it is being converted.

The drug just targets the active prostate form.

However, because we are shrinking physical tissue via apoptosis, you have to remember, this is not a quick fix.

Right.

Taking the cargo out of the trunk box by box takes time.

A lot of time.

Clinical guidelines emphasize that prostate shrinkage occurs slowly over like 6 to 12 months.

Okay.

So that is a crucial patient education point.

Because if you prescribe finasteride, you have to tell your patient not to expect immediate relief.

Otherwise, they will just assume the drug isn't working and they'll stop taking it.

Exactly.

Adherence is a huge issue there.

But here's where it gets really interesting.

I want to talk about the black box level warnings and safety alerts in the text.

Specifically, that bizarre paradox regarding prostate cancer.

Yeah, it is a very significant clinical paradox.

Because finasteride drops DHT and shrinks the prostate, it logically protects against prostate cancer.

Right.

That makes intuitive sense.

And trials showed exactly that.

But only for cancers classified as low grade.

It does not protect against high grade prostate cancer.

Wait, really?

Yeah.

In fact, clinical trials reveal that when healthy patients took finasteride simply to prevent prostate cancer, it actually increased the likelihood of them developing a high grade aggressive tumor.

That is terrifying.

Why does that even happen?

Well, the exact mechanism is still debated, but the leading theory is that by suppressing DHT, you create a sort of selective survival environment.

What does that mean?

So the low grade androgen dependent cancer cells die off.

But if any high grade androgen independent cancer cells are present, they now have zero competition for space and resources.

Oh, wow.

So they just rapidly proliferate.

Exactly.

And that is why the FDA strongly advises against using five ARIs for prostate cancer prevention.

They are strictly for BPH or at much lower doses male pattern baldness.

Okay.

So we only prescribe it for the hyperplasia.

Got it.

So what other adverse effects are we monitoring for?

Well, in about five to 10 % of patients, you will see decreased ejaculate volume and decreased libido.

And that's purely due to the local androgen suppression in the reproductive tract.

Right.

Some patients also develop gynecomastia.

But the real clinical trap here is that these sexual changes can occasionally persist even after the medication is stopped.

Oh, really?

That's a tough conversation to have.

It is.

So you really have to establish an open dialogue with your patient about their sexual health before initiating therapy.

Absolutely.

And we absolutely must talk about the teratogenic risks because this goes way beyond just telling a pregnant patient not to take the drug.

Finasteride is highly teratogenic to an XY fetus.

Yes, very much so.

It disrupts the androgen -dependent virilization of the male external genitalia during the first trimester.

But the text makes it clear it's not just about ingestion, right?

It's about simply handling the medication.

Right.

The pharmacokinetics of finasteride make it highly lipid soluble, which means it absorbs really rapidly right through the epidermal barrier.

Oh, wow.

So through the skin.

Yes.

If a tablet is crushed or broken, the active drug can be absorbed directly through the skin of whoever touches it.

If that person is pregnant, the drug readily crosses the placenta.

That's intense.

So clinicians must explicitly instruct patients to keep these medications far away from pregnant partners.

Absolutely.

It even impacts the community blood supply, which blew my mind.

A patient on finasteride cannot donate blood until at least one month has passed after stopping the drug.

Right.

Just to completely eliminate the risk of a pregnant individual receiving a transfusion that contains the drug.

Such a wild systemic effect.

And speaking of vigilance, that monitoring requires absolute precision, particularly when we look at PSA.

Oh, PSA is a huge one.

Prostate specific antigen is primarily produced by the epithelial cells of the prostate.

So since finasteride shrinks the epithelial tissue, it artificially lowers serum PSA levels by about 30 to 50%.

Okay.

Let's do the clinical math on that because it's a massive prescribing trap.

If you don't get a baseline PSA before starting finasteride, you are just completely flying blind.

Basically.

Yeah.

Say a patient's baseline PSA is 4 .0.

You start them on finasteride.

Six months later, you check it and it's still 4 .0.

You might think, great, it's stable, but it's not stable, is it?

Not at all.

If the drug is actually working, that 4 .0 should have therapy.

Their true PSA has actually doubled to 8 .0 and the drug is just masking the spike.

Wow.

So if the PSA fails to fall as expected, the clinician has to immediately evaluate for prostate cancer.

Exactly.

It's a huge red flag.

Okay.

So that is finasteride.

We also have detasteride.

If they are in the exact same class, what is the clinical distinction?

Why would you choose one over the other?

Well, detasteride is essentially the heavy duty version.

Finasteride only inhibits the type two isoenzyme of five alpha reductase, which is primarily in the reproductive tissues.

Okay.

Detasteride, on the other hand, inhibits both type one and type two isoenzymes.

That means it blocks DHT production in the skin and liver as well.

Oh, so a much broader effect.

Yeah.

The result is a much deeper reduction in circulating DHT, about 93 % compared to finasteride 70%.

Wait, let me push back on that for a second.

If detasteride is wiping out 93 % circulating DHT systemically, shouldn't we expect like catastrophically worse adverse effects compared to finasteride?

You know, you would logically think so, but clinical data actually shows their adverse effect profiles are remarkably similar.

Really?

How is that possible?

Both cause the same rates of decreased libido and ejaculatory dysfunction.

It turns out that for these specific side effects, dropping DHT by 70 % hits the exact same symptomatic threshold as dropping it by 93%.

Oh, that is fascinating.

So the extra drop doesn't make the side effects worse.

Right.

The main clinical difference isn't the side effects.

It's actually the pharmacokinetics.

Detasteride is highly lipophilic with a massive volume of distribution, which gives it an extremely long half -life of about five weeks.

Five weeks.

That is huge.

That means it takes months to achieve a steady state and months to clear from their system, which completely explains the blood donation role.

Finasteride requires a one -month wait to donate blood.

For deutasteride, because of that massive half -life, the patient has to wait at least six months.

Spot on.

And just a quick clinical pearl on administration, deutasteride capsules absolutely cannot be opened to sprinkled on food.

Oh, right.

Because of the mucosa?

Yeah.

The contents are highly irritating to the oropharyngeal mucosa.

So it just has to be swallowed whole.

Good to know.

So just to summarize the five ARIs, they target the epithelial tissue, they reduce the mechanical cargo, and they take six to 12 months to really work.

Exactly.

But let's go back to our clinical scenario.

Your patient in the exam room is in agony today.

They have that dynamic obstruction.

The emergency break is fully engaged on the bladder, neck, and urethra.

They cannot wait six months for apoptosis.

No, they need relief right now.

And that is exactly where we turn to the alpha -1 adrenergic antagonists, or alpha blockers.

Okay, so how exactly are these releasing the emergency break?

Well, by blocking alpha -1 receptors, these drugs cause rapid relaxation of the smooth muscle in the bladder neck, the prostate capsule, and the prostatic urethra.

And that works?

Quickly.

Very quickly.

By relaxing that muscle tone,

symptomatic improvement and increased urinary flow develop rapidly, often within just a few days.

Wow, that's a huge difference from the five ARIs.

It is.

But it is vital to remember they do not reduce the size of the prostate, they don't touch the cargo at all, and because of this, they must be taken lifelong to maintain the benefits.

Okay, so this is where the clinical decision framework gets a bit intricate.

We have five alpha blockers approved for BPH.

They're divided into non -selective agents, which are alfizosin, cherizosin, and doxizosin, and selective agents, which are acylidosin and tamsilosin.

Right.

So what drives the decision to prescribe selective versus non -selective?

It all comes down to receptor location.

The non -selective agents block alpha -1A receptors in the prostate, but they also block alpha -1B receptors in the blood vessels.

Okay, and when you block receptors in the vascular smooth muscle, you cause vasodilation, which lowers blood pressure.

Wait, let me stop you there, because that sounds like a brilliant two -for -one deal.

I mean, most of our BPH patients are older men.

If they have BPH and hypertension, why not just prescribe doxizosin, block all the receptors, and fix both problems with one single pill?

You know, and that specific comorbidity, it can be a highly rational choice, but it poses a severe danger to normotensive patients.

How so?

If you give a non -selective agent to a patient with normal blood pressure, that systemic vasodilation causes profound orthostatic hypotension, fainting, and dizziness.

Oh, wow.

So they stand up and just pass out.

Exactly.

The risk is so high that the Beers criteria, which flags inappropriate medications for older adults,

explicitly warns against doxizosin and terezosin due to the severe risk of falls and subsequent fractures.

Okay, which is why for the vast majority of normotensive patients, we prefer the selective agents, celidosin or tamicelosin.

Correct.

The selective agents specifically target the alpha -1A receptors localized just in the prostate and bladder neck.

Because they bypass the vascular receptors, they maintain blood pressure stability.

That's a huge relief.

It is, but that high selectivity brings a unique adverse effect.

They frequently cause abnormal ejaculation,

specifically ejaculation failure, or retrograde ejaculation.

Retrograde ejaculation.

Why does selective prostate blockade cause that?

What is the actual mechanism there?

So during normal ejaculation, the internal urethral sphincter at the bladder neck has to contract really tightly, and that's driven by alpha -1A receptors to propel semen forward out of the urethra and prevent it from shooting backward into the bladder.

Okay, I follow.

Because tamicelosins and celidosins specifically block those alpha -1A receptors, the sphincter remains relaxed and open during ejaculation.

The path of least resistance is actually backward, so the semen enters the bladder.

That is fascinating.

I mean, it's harmless, but highly distressing for the patient if you don't educate them beforehand.

Absolutely, you have to warn them.

Now, speaking of unexpected adverse effects, there is a safety alert with alpha blockers that I want to highlight because it honestly sounds almost made up.

Intraoperative floppy iris syndrome.

Yeah, that's a real thing.

How on earth does a prostate drug affect the eye?

It's a perfect example of system -wide receptor biology, actually.

The iris dilator muscle in the eye relies on alpha -1 receptors to maintain its structural rigidity and control people dilation.

Okay.

So when a patient is on an alpha blocker, that muscle tone is lost.

If they undergo cataract surgery, the flaccid iris can billow like a sail, hence the name floppy iris.

Oh, wow.

Yeah, and it complicates the surgery, increases post -operative pain, and in severe cases, it can cause iris defects that literally lead to blindness.

Imagine causing permanent eye damage just because you didn't ask about an upcoming cataract surgery when prescribing for BPH.

It's completely preventable, too.

Right.

Clinicians must advise any patient anticipating eye surgery to postpone alpha blocker therapy until after the procedure.

And if they are already on it, they have to alert their ophthalmologist immediately so surgical techniques can be adjusted.

Exactly.

Communication is key there.

Okay.

Let's talk drug interactions.

What are the major prescribing traps for alpha blockers?

Well, there are two critical pharmacokinetic traps.

First, if you prescribe a non -selective alpha blocker alongside other vasodilators, specifically organic nitrates like nitroglycerin or PDE5 inhibitors used for erectile dysfunction like sildenafil, the additive vasodilation can cause a catastrophic, life -threatening hypotensive crash.

A severe drop in blood pressure.

Yes.

Very dangerous.

And the second interaction is a metabolic bottleneck in the liver, right?

Yes, specifically the CYP3A4 pathway.

Drugs like alfuzosin and cilidosin rely heavily on the CYP3A4 enzyme for metabolism.

Okay.

If a patient is taking a strong CYP3A4 inhibitor like, say, the antibiotic erythromycin, the antifungal etriconazole, or an HIV protease inhibitor like rotonavir, the liver is just too busy processing the inhibitor.

So the alpha blocker just builds up.

Exactly.

It can't be metabolized, so as blood levels spike to toxic concentrations, they are strictly contraindicated together.

So what does this all mean for our clinical strategy?

We have 5 -ARIs that work slowly to reduce the mechanical power go.

We have alpha blockers that work instantly to release the dynamic emergency break.

From a pathophysiological standpoint, why not just use both?

Well, clinical data confirms that it is actually often the superior approach.

Really?

Yeah.

Combining an alpha blocker with a 5 -ARI tackles BPH from both angles simultaneously,

the alpha blocker provides rapid symptom relief today, while the 5 -ARI slowly shrinks the prostate over the next year to delay overall disease progression.

That's amazing.

We even have combination formulations now, like Jalen, which actually combines Tamsulosin and detastride into a single daily capsule just to improve patient adherence.

That synergy is fantastic.

Now, what about the patient who presents with BPH but also complains of erectile dysfunction?

We just discussed PDE5 inhibitors as a severe contraindication for non -selective alpha blockers, but one of them, Tadalafil, is actually FDA approved to treat BPH.

It is approved, yes, but we need to offer a bit of a clinical reality check here.

Okay, wait on me.

Tadalafil relaxes smooth muscle in the prostate and bladder, but the clinical trials show it really only produces a modest decrease in symptoms like urgency and frequency.

So it's not a miracle cure?

No, it does not meaningfully improve urinary flow rates, and statistically only about one in six patients actually experience a significant benefit.

And of course, if you do prescribe Tadalafil, that absolute contraindication with nitrate still fully applies.

So it's an option if ED is the primary comorbidity, but it's definitely not a silver bullet for the BPH.

What else is in our pharmacological toolkit?

Well, if a BPH patient is concurrently experiencing overactive bladder symptoms, like profound urgency and frequency, we can utilize anticholinergics.

Like which ones?

Specifically, anti -muscarinics like oxybutynin or tolterdine.

They block the muscarinic receptors in the detrusor muscle, which reduces bladder spasms.

They can be used effectively on their own or even combined with an alpha blocker.

Nice.

And then we have botulinum toxin or Botox.

I marvel at this every time I see it used outside of neurology or dermatology.

Are we seriously injecting Botox directly into the prostate?

We are indeed.

A single injection blocks the release of acetylcholine from the neurons innervating the urinary tract smooth muscle.

Oh, wow.

It forces the muscle to relax, which drastically eases the dynamic obstruction, and the relief can last for up to a full year.

A full year?

That makes perfect sense for a dynamic obstruction, but there is a mystery here, isn't there?

Yes, there is.

Based on its mechanism, Botox should really only affect the muscle, but clinical imaging shows that Botox injections also reduce the overall physical size of the prostate, and they lower serum PSA levels.

Wait, how?

We honestly don't fully understand how blocking acetylcholine causes epithelial apoptosis, so there must be other biological mechanisms at play that we just haven't mapped out yet.

A little pharmacology mystery to keep us humble.

I love it.

Now, before we wrap up, we have to address the inevitable clinical scenario.

Complementary and alternative medicine, yes.

A patient comes in holding a bottle of Saw Palmetto they bought over the counter.

They want to take it instead of a prescription.

How does the advanced practitioner respond to that?

You have to rely on the rigorous data.

For years,

small, poorly controlled studies suggested Saw Palmetto might inhibit 5 -alpha reductase.

Oh, I've heard that.

But the definitive word came from a massive Cochrane review involving over 4 ,600 subjects.

It conclusively proved that Saw Palmetto makes little to no difference in urologic symptoms or urinary flow compared to a placebo.

Wow, so it's basically useless for BPH.

Yeah.

Based on this, the American Urological Association clinical guidelines explicitly declined to recommend any dietary supplement or herbal treatment for BPH.

We follow the evidence.

Okay, we have covered an immense amount of ground today.

Let's try to synthesize the clinical logic.

Sounds good.

The successful management of BPH relies entirely on the specific mechanism of obstruction to the correct drug class.

If the patient has a bulky prostate causing a mechanical obstruction,

you prescribe a 5 -alpha reductase inhibitor to starve the tissue of DHT and shrink it over several months.

Right.

While hypervigilantly monitoring PSA levels and warning about teratogenic risks.

Exactly.

And if they have a dynamic obstruction causing immediate misery, you prescribe an alpha blocker to rapidly relax the smooth muscle.

And you carefully select between selective and non -selective agents based on their blood pressure while warning them about floppy iris syndrome and retrograde ejaculation.

And if we connect this to the bigger picture, it leaves us with an important final thought.

It really does.

When you are deep into pharmacokinetics, it is so easy to view these drugs as just isolated chemical interactions inside one single patient's urinary tract.

It is.

But consider the profound system -wide responsibility of prescribing a drug like an asteroid.

You are writing a script that dictates how a patient handles a pill in their own home around a pregnant partner.

Yeah, that's heavy.

You are prescribing a medication that alters their eligibility to donate blood to their community.

It perfectly illustrates how highly localized treatments,

shrinking a tiny gland the size of a walnut ripple,

out to have systemic and even community -wide implications.

That is an incredibly powerful perspective to carry into your practice.

It's exactly why we have to deeply understand the how and the why, not just the what.

Well, that brings us to the end of our BPH deep dive.

From every one of the last minute lecture team, we want to deliver a huge warm thank you for spending this time with us.

We know exactly how intense advanced practice nursing and PA programs are.

We do.

And we are rooting for your success.

Keep pushing.

Good luck on your clinical rotations.

Good luck on those exams, and we will see you on the next deep dive.